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tasis. The 1- and 5-year post-hepatic transplantation survival rates among patients 
subjected to bone scintigraphy were 81% and 69%, respectively; those among patients 
not subjected to scintigraphy were 78% and 62%, respectively (p = 0.25). The 1- and 
5-year post-HTx recurrence rates among patients subjected to bone scintigraphy were 
4.8% and 10.7%; those among patients not subjected to scintigraphy were 2.9% and 
10.1%, respectively (p = 0.46). Results: The cost generated by the current evaluation 
policies, US$ 27.582, did not result in the detection of any sub-clinical metastasis and 
therefore failed to provide positive cost-effectiveness. ConClusions: Clinical evi-
dence has demonstrated that bone scintigraphy did not provide aditional information 
about patient selection since the incidence of metastasis in early stages is very low. 
In our cohort, the use of scintigraphy in the assessment of patients with early stages 
of HCC and within the Milão criteria, included in a liver transplant list by dead donor, 
in a center in the south of Brazil, had zero benefit.
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objeCtives: To determine the cost-utility of continuing education for the man-
agement of patients with type 2 Diabetes Mellitus (T2DM), in Pernambuco - 
Brazil. Methods: It’s a cost-utility evaluation, using the Markov model to simulate 
the results in health scenarios, from the perspective of the health system. It was 
considered an analytic horizon of 20 years and selected the category of direct medi-
cal costs. Data were obtained from primary source, SERVIDIAH study, and secondary 
sources from health information systems and literature. The reference scenario 
represents the standard health care management performed in public health ser-
vices. The simulated scenarios for post-intervention’s results were based on the 
suggestion of consulted experts in regard the effectiveness of continuing education 
for health professionals in primary health care (PHC) for the patient’s complications 
reduction. Results: The average individual, representative Pernambuco’s popula-
tion, was female, 61 years old and diagnosed with T2DM for 8.7 years. These and 
other clinical characteristics that influence the calculation of the transition prob-
abilities were gathered from over 800 patients with T2DM from Pernambuco. For the 
reference scenario, the cost for one individual was calculated for the intervention’s 
first year, 2011: without complications (U$ 491.04), with microvascular complications 
(U$ 774.23), macrovascular complications (U$ 1,945.95) and both complications (U$ 
2,229.14). The incremental cost for the implementation of the intervention was 
U$ 242.42 per individual/year, later added to the cost for standard management 
in the post-intervention scenarios. At the cost-utility evaluation, only the first 
simulated scenario (Very Satisfactory Result) was cost-effective, with Incremental 
Cost-effectiveness Ratio (ICER) of U$ 7,362.70/QALY. ConClusions: The ICER pre-
sented suggests that the intervention isn’t a cost-effective alternative. Given the 
uncertainties about the effectiveness of continuing education for professionals in 
the PHC on the health of users, it is necessary to conduct in-depth studies on the 
association between these variables.
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objeCtives: To critically appraise published pharmacoeconomic studies of 
two novel antiplatelet (AP) agents (ticagrelor and prasugrel) in the treatment 
of acute coronary syndromes (ACS). Methods: Key terms related to economic 
evaluations of ticagrelor and/or prasugrel were searched in EMBASE, MEDLINE and 
International Pharmaceutical Abstracts. English-language articles evaluating the 
use of these agents in adults with ACS were included. Studies assessing genotyp-
ing-guided treatments were excluded. Elements of each study were independently 
extracted based on the ISPOR Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) checklist by two reviewers. Results: Eleven (7 ticagrelor, 4 
prasugrel) studies were identified, 7 of which included both cost-effectiveness 
and cost-utility analysis. No comparisons were made between prasugrel and 
ticagrelor and each agent was compared to clopidogrel. The manufacturer of the 
novel AP funded all but one study. Most models were Markov-based simulations, 
with almost all studies adopting a healthcare system perspective and lifetime 
time horizon. Two randomized-control trials (RCTs), PLATO and TRITON-TIMI 38 
were most commonly cited for ticagrelor and prasugrel, respectively, with few 
non-RCTs used for clinical data input. While methods to derive the efficacy data 
were commonly reported, utility estimates varied for some health states between 
studies using the same data by the same sponsor. Both ticagrelor and prasugrel 
were deemed cost-effective vs. clopidogrel in base-case analyses. ConClusions: 
Studies would benefit from greater consistency in sources of costing data and 
estimates of utility values and decrements. There is a clear reliance on single mul-
tinational RCTs as the primary data source for the vast majority of model inputs, 
and the PLATO study has been heavily criticized for issues related to external 
validity. More independent, non-industry sponsored economic evaluations and 
real-world clinical data are required in the future. Reporting checklists do not 
capture these latent issues behind economic evaluations, as identified by our 
appraisal of the literature.
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further investigation as a way to detect, characterize, and address bias in retrospec-
tive samples.
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objeCtives: In clinical trials of early-stage prostate cancer, demonstration of an 
overall survival (OS) benefit is challenging because of prolonged patient survival. 
While the development of metastasis is a major milestone in the disease, payers 
are interested in understanding the clinical relevance of metastatic-free survival 
(MFS) as a surrogate endpoint and its relationship with long-term outcomes, in 
particular, OS. The objective of the current study was to identify empirical evi-
dence evaluating MFS in patients with prostate cancer. Methods: A structured 
literature review was conducted in PubMed (1999−2014) to identify clinical trials in 
prostate cancer using MFS as a primary endpoint, and clinical and observational 
studies that evaluated the association between MFS and OS. Results: Three 
published clinical trials used MFS as a primary endpoint. The studies employed 
varying definitions for MFS (e.g., bone metastasis only or bone and soft tissue 
metastasis). In one long-term study comparing adjuvant radiotherapy to usual 
care, both MFS and OS outcomes were significantly improved with radiotherapy, 
suggesting a relationship between these two endpoints. Four additional studies 
examined the association between MFS and OS. One study reported that dis-
tant metastasis at three years met the Prentice criteria for surrogacy of prostate 
cancer-specific survival at 10 years. A second study reported that MFS was one of 
four independent prognostic variables for OS in prostate cancer. The remaining 
two studies demonstrated that time to metastasis was significantly associated 
with prostate cancer-specific mortality. ConClusions: MFS has been used as 
the primary endpoint in several prostate cancer studies, providing support for the 
clinical relevance of this outcome. Current evidence from the literature suggests 
an association between MFS and OS, however additional research is needed to 
further investigate this relationship.
REsEaRCh on MEthods – Cost Methods
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objeCtives: The IMS CORE Diabetes Model (CDM) is a widely published and 
validated decision support tool. The model uses UKPDS68 and UKPDS82 risk 
equations (REs) to predict events and has been updated to include REs from the 
Swedish-National-Diabetes-Registry (S-NDR) and the ADVANCE-Risk-Engine 
(A-RE). The objective of this study was to compare and contrast cardiovascular 
(CV) incidence and cost-effectiveness (CE) across these four REs. Methods: 
Lifetime analyses comparing the CE of metformin+ sulphonylurea (M+S) versus 
metformin + DPP-4 (M+D) was undertaken using the CDM. Basal insulin rescue 
therapy (BI) was applied to both arms at HbA1c threshold levels of 7.5%. Efficacy 
data for dual therapy was sourced from a published mixed treatment compari-
son; HbA1c and BMI change at one-year of -0.8% and 0.199kg/m2 (M+D);-0.79% 
and 0.707kg/m2 (M+S) and -0.82 and 0.545 kg/m2 (BI), respectively, were applied. 
Hypoglycemia rates were taken from the same systematic review. US 2012 costs 
were used and discounting was applied at 3.0%. Results: In the base analysis 
(UKPDS68) predicted CV incidence for myocardial infarction, stroke, ischemic 
heart disease and heart failure was 31.42%, 15.59%, 12.85% and 21.01%, respec-
tively, for patients treated with M+D and 31.39% , 15.23%, 12.51% and 21.26% for 
patients treated with M+S. This compared to 26.72%, 14.31%, 17.96% and 12.74% 
(M+D) and 26.02%, 13.94%, 17.91% and 13.43% (M+S) using UKPDS82 REs; 30.19%, 
52.93%, 6.42% and 6.22% (M+D) and 29.7%, 53.98%, 6.23% and 6.5% (M+S) using 
S-NDR REs and 42.62%, 15.05%, 11.98% and 19.56% (M+D) and 42.17%, 15.1%, 
11.97% and 20.46% (M+S) using A-RE REs. Incremental cost per quality adjusted 
life years were estimated at $78,537 (UKPDS68); $77,594 (UKPDS82); $70,054 
(S-NDR) and $74,783 (A-RE). ConClusions: There was a noteworthy difference 
in predicted CV incidence across the four equations; however, CE results were 
relatively stable. Consequently, choice of RE appears unlikely to significantly 
impact CE.
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objeCtives: Evaluate for the first time in Brazil the pertinence of systematically 
requesting whole-body bone scintigraphy in early-stage HCC adult patients as a 
requisite for inclusion on the waiting list for HTx from a deceased donor, according 
to a reference center in South Brazil. Current pre-transplantation evaluation policy 
includes mandatory bone scintigraphy as a requisite for selecting patients to be 
included on hepatic transplantation list. Previous studies, however, have shown that 
routine scintigraphy is not cost-effective and generates unnecessary Health System 
costs. Methods: We retrospectively analyzed 256 medical files of early-stage HCC 
patients who underwent hepatic transplantation, 187 of whom were subjected to 
pre-transplantation bone scintigraphy. The most common etiology was hepatitis C 
viral infection, the most common liver functional class was Child B, and 78% of the 
patients met the Milan criteria. None of the 187 scintigraphies was positive for metas-
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ers of overuse across HRRs in the US. Structural variations imply that the causes of 
widespread overuse can be identified and potentially controlled.
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objeCtives: Much recent debate has focused on the merits of differential discount-
ing of costs and health effects. Yet relatively little attention has been paid to the 
merits of using discount rates that are time-dependent (i.e. non-constant). Recent 
theory shows that appropriate discount rates depend upon the real rate of borrow-
ing. Since this is determined by the bond market, and since real yields differ on 
bonds of different maturity, this implies that discount rates ought to be non-con-
stant. Recent research has also demonstrated that conventional objections to non-
constant discounting, such as the risk of time-inconsistency, may no longer hold. 
Our objective is to shed light on this under-researched topic and to ignite a debate 
about the merits of non-constant discounting. Methods: We review the theoreti-
cal and empirical literature around the use of non-constant discounting, consider 
whether non-constant discounting is appropriate for social decision making, and 
(if so) propose how decision makers can incorporate non-constant discounting in 
a way that is time-consistent and which accounts for intergenerational equity and 
other social value considerations. We also consider, and propose solutions to, tech-
nical hurdles associated with adopting non-constant discounting. Results: The 
conventional approach to discounting (using a constant rate) is appropriate only 
in special cases where specific assumptions are adopted. In general, non-constant 
discounting is preferable. Recent work has overcome both the theoretical and tech-
nical hurdles to the adoption of non-constant discounting ConClusions: Decision 
makers should reconsider their existing discounting methodology to ensure that it 
is compatible with their perspective on social choice, any budget constraints faced, 
and other considerations. Where non-constant discounting is found to be appropri-
ate, it should be embraced by decision makers.
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objeCtives: estimate the per capita income and the global attention expenditure 
for a person that is part of the contributive health subsystem, through an econo-
metric model, using a clinical diagnosis group of patients, which permit the suf-
ficiency resources evaluation. Methods: Using an econometric model developed 
from information detailed health expenditure of 9.6 million members attended and 
unattended in four different insurers, he sought to build an explanation of expendi-
ture information 2013, using three categories of variables: sociodemographic (age, 
sex), chronic (ten groups) and risk factors. To estimate the function a multiple regres-
sion was used to identify statistically significant variables that explain spending 
the best model, low goodness of fit and reporting criteria. Reliability tests on indi-
vidual basis and robustness tests for each variable and the model generally applied. 
Furthermore, deviations between different insurers were identified. Results: The 
final linear function includes 18 different variables, all significant at 10%, with an R2 
of 7.03%. The estimation shows that men are spending on average lower than that of 
women. The differences in betas by age groups were not significant, but different in 
the groups with chronic diseases and comorbidity. Can be estimated average costs 
for patients with chronic diseases. When testing model fit on the same database, 
there is a goodness of fit of 99%, where health spending in real per capita was $ 
447,375 versus estimated by the model equals $ 447,370. ConClusions: estimating 
a model that includes variables associated with the disease gives higher accuracy 
than when only demographic variables are used and allow a more equitable dis-
tribution of risk-based resources and could be a better alternative in defining the 
insurance premium for a country like Colombia.
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objeCtives: To review the issues in calculating confidence intervals (CIs) of the 
incremental cost-effectiveness ratio (ICER) with conventional methods and to pro-
pose new methods defining more appropriate ranges to evaluate the uncertainty 
of cost-effectiveness analysis. Conventional methods to calculate CIs first obtain 
the cost-effectiveness plane through Monte Carlo simulation. Next, 95% of the 
distribution is surrounded with two lines that pass through the origin, and the 
slopes of these two lines will be assumed to be the upper and lower CIs. In some 
situations, the methods yield CIs that are separated as -∞to upper limit and lower 
limit to ∞. On the contrary, CIs are not defined if any two lines surround 95% of the 
distribution. Methods: We propose two modifications on methods for construct-
ing ICER CIs. One is to surround 95% of the distribution with two segments from 
the origin (method 1). Another is to report just the upper or lower limit defined in 
the first quadrant if the CIs are not appropriately defined (method 2). We evalu-
ated the performance of the existing and proposed methods (method 1, method 
2 and a combination of both) using simulations that calculate ICER CIs on three 
situations. Results: Our simulations revealed that the results from the proposed 
methods are similar to those from the conventional ones under the situation that 
the latter can yield the fair CIs (situation 1). However, under the situations that con-
ventional methods cannot appropriately define the CIs (situation 2; CIs separated, 
objeCtives: Previous reviews of cost-effectiveness analyses (CEAs) of varicella 
vaccination have concluded that dynamic transmission models should be used 
to properly account for indirect effects of vaccination. This study reviews CEAs of 
varicella vaccination that used a dynamic model to identify parameters with the 
greatest impact on the CEA results. Methods: A targeted search of MEDLINE was 
conducted for childhood varicella vaccination CEAs that used a dynamic model. We 
assessed the structural assumptions and input parameters that had the greatest 
impact on the cost-effectiveness results and summarized the ranges of input val-
ues and primary data source. Results: Fourteen varicella vaccination CEAs using 
a dynamic transmission model were identified. The results of these studies were 
most sensitive to 2 structural assumptions: 1) inclusion of zoster and 2) inclusion 
of indirect costs. For example, whether or not zoster was included changed results 
from “cost saving” to exceeding country-specific thresholds for cost-effectiveness. 
These results depended on the assumed magnitude of the impact of varicella vac-
cination on zoster cases and the time horizon for the CEA. Three input parameter 
values also substantially impacted the results: 1) vaccine-related costs depending 
on if 1 or 2 doses of vaccine were evaluated, 2) estimates of productivity loss per case 
of varicella (0.27 to 8.8 days for caregivers of children, 2.6 to 26.1 days for adults) and 
3) estimates of QALY loss per case of natural varicella (0.0027 to 0.004 [uncompli-
cated case], 0.0038 to 0.017 [complicated case]), per case of breakthrough varicella 
(20% to 50% of natural case value), and per case of zoster (0.01 to 0.12 [younger/
less severe case], 0.201 to 0.52 [older/more severe case]). ConClusions: Future 
research should be prioritized for epidemic and economic parameters for which 
there is large uncertainty and that impact the results and, consequently, decisions 
about varicella vaccination programs.
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objeCtives: Health technology appraisal bodies such as NICE in the UK have 
shown interest in using the absolute and proportional quality adjusted life year 
(QALY) shortfall to represent aspects of disease burden. NICE originally proposed in 
their value based assessment consultation paper that additive cost-effectiveness 
threshold weightings could be applied according to both the absolute and pro-
portional QALY shortfalls. This analysis sought to understand the relationship 
between the absolute and proportional shortfall and therefore whether the pro-
posal by NICE was justified. Methods: The conditions selected were identified 
from NICE single technology appraisals published between July 2011 and December 
2014. The age that treatment commenced was taken from manufacturer models 
and combined with the gender-dependent average life expectancy and age- and 
gender-dependent utilities in the UK to calculate the discounted QALYs accrued 
by a healthy person (X). Discounted QALYs accrued by current treatment were 
extracted from manufacturer submissions (Y). Consequently, absolute (X-Y) and 
proportional (absolute/X) QALY shortfalls were calculated for each condition. The 
data were analysed using linear OLS regression, with the absolute shortfall being 
the dependent variable. Appraisals were excluded if the manufacturer submission 
was missing or if the time horizon was not lifetime. Results: The absolute and 
proportional QALY shortfalls were calculated for 43 conditions. The regression 
line had equation y = 13.0x + 0.005 and the r-squared value was 0.84, indicating 
that there is a strong positive correlation between absolute and proportional QALY 
shortfall. This is not surprising given that the variables are mathematically cou-
pled. ConClusions: Absolute and proportional QALY shortfall are not independ-
ent variables, but are mathematically related, and therefore bodies such as NICE 
should avoid assigning additive weights to these measures. If additive weights 
were assigned, conditions where the QALY does not fully capture the benefits of 
new technologies would be particularly disadvantaged.
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objeCtives: The Johns Hopkins Overuse Index (JHOI) was designed as a composite 
measure of systematic overuse that was operational in claims data. Unlike measures 
of geographic variation, it uses detailed algorithms to identify instances where the 
procedure is used in patients that are unlikely to benefit. Using multi-level modeling 
techniques to measure overuse across 306 Hospital Referral Regions (HRRs), the 
JHOI has been shown to be highly predictive of higher costs and worse outcomes 
in an HRR. The purpose of this study was to explore possible drivers of overuse by 
comparing the overuse index to structural indicators available in the Dartmouth 
Atlas. Methods: A normalized JHOI was derived for 306 HRRs using a 5% sample 
of Medicare claims from 2008 and reflected overuse within each HRR. Inpatient 
and outpatient claims were used and claims from nursing homes were excluded. 
Potential drivers of overuse were derived from Dartmouth Atlas and regressed upon 
JHOI using ordinary least squares (OLS). Lagged covariates were used to prevent 
reverse causation. Huber-White standard errors were used to address clustering of 
HRR within states. Results: Exploratory analyses identified that the JHOI was posi-
tively associated with the number of acute-care beds (p< 0.001), medical specialists 
(p< 0.005), surgeons (p< 0.001), and the number of Medicare beneficiaries (p< 0.01) in 
an HRR. Regions with higher rates of appropriate testing of patients with diabetes 
(a proxy of process quality) (p< 0.05), more physicians (p< 0.001), and more nurses 
(p< 0.001) had less systematic overuse. ConClusions: The use of cross-sectional 
data, collinearity between possible explanatory variables, and the relatively large 
unit of observation limit the interpretation of these findings as causal. This said, 
the intuitive nature of these findings suggests that there are likely structural driv-
